News: Inovio Pharmaceuticals Inc (INO.A)
INO.A on American Stock Exchange
0.91USD
12:23pm EDT
0.91USD
12:23pm EDT
Price Change (% chg)
$0.02 (+2.44%)
$0.02 (+2.44%)
Prev Close
$0.89
$0.89
Open
$0.94
$0.94
Day's High
$0.96
$0.96
Day's Low
$0.90
$0.90
Volume
333,390
333,390
Avg. Vol
144,156
144,156
52-wk High
$1.00
$1.00
52-wk Low
$0.44
$0.44
Select another date:
Select another date:
- Could Upcoming Catalysts Carry On The Epic Year For Inovio?
- Inovio Pharmaceuticals: 2 100% Results In 2 Months
- Sorting Out Inovio Claims
- Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals
- A Comprehensive Overview Of Active Electroporation Cancer Trials
- Inovio Pharmaceuticals: Why Best Therapeutic Vaccine Award In 2013?
Press Releases
- Today's Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
- Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
- Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
- Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
- Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
- Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
- Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
- Today's Technical View on Sequenom, Peregrine Pharma, Inovio Pharma, and Onyx Pharma
- Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
- Inovio Pharmaceuticals to Present at BioCentury's "Future Leaders in the Biotech Industry" Conference
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
